CODX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$4.00median target· current $0.37 (+990.8%)1 analyst
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 15.36
EPS (TTM)$-26.1430.8% YoY
Profit margin0.0%HEALTHCARE
Market cap$3.2MMicro cap
Valuation
- Forward P/E
- 15.36
- PEG ratio
- 0.00
- P/B
- 0.27
- P/S (TTM)
- 4.49
- EV/EBITDA
- 0.52
Profitability & growth
- ROE (TTM)
- -174.8%
- Operating margin
- -3732.0%
- Revenue growth YoY
- 2.0%
- Dividend yield
- —
- Beta
- 2.90
Last earnings
Aug 13, 2026 · Estimate $-3.00 · Reported $-1.46
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Co-Diagnostics, Inc. Common Stock
Company profileCo-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.
Classification
- Sector
- Healthcare
- Industry
- Medical Devices
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 2401 S. FOOTHILL DRIVE, SALT LAKE CITY, UT
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$3.2M
Shares outstanding$8.8M
52W high$13.80
52W low$0.37
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent